查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026751

臨床前受託研究機構(CRO) 市場預測至 2034 年—按模式類型、服務、動物模型、最終用戶和地區分類的全球分析

Preclinical Contract Research Organization Market Forecasts to 2034 - Global Analysis By Model Type, Service, Animal Model, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球非臨床合約研究組織 (CRO) 市場預計將在 2026 年達到 64 億美元，並在預測期內以 9.5% 的複合年成長率成長，到 2034 年達到 132 億美元。

臨床前合約研究組織 (CRO) 是製藥和生物技術行業中專門服務供應商，負責在實驗性藥物和治療方法進入臨床試驗之前進行研究和測試。臨床前 CRO 提供廣泛的服務，用於評估新型化合物的安全性、有效性和潛在風險。此外，他們的知識和資源還能提供關鍵資訊和法規支持，幫助製藥公司最佳化藥物開發流程，確保符合監管和行業標準。

根據國際藥品製造商協會聯合會 (IFPMA) 2021 年的報告，國際生物製藥產業的年度研發支出是航太和國防產業的 7.3 倍，是化學產業的 6.5 倍，是軟體和電腦服務業的 1.5 倍。

全球化進程

合約研究組織 (CRO) 是一家國際性機構，為製藥和生物技術公司提供跨多個司法管轄區的廣泛資源、知識和監管管道。透過利用監管優勢、多元化的患者群體和新興市場，企業可以最佳化其全球藥物研發策略。此外，透過促進合作與創新，加快新藥上市速度並提高效率，CRO 能夠改善醫療保健效果，並增強大眾獲得前沿治療方法的機會。

高成本

由於需要遵守嚴格的監管要求並維持品質標準，成本不斷增加。為了妥善進行臨床前研究，CRO 必須在先進的設施、設備和高素質人才方面投入大量資金。 CRO 產業競爭激烈，這推高了行銷和業務拓展活動的成本。此外，這些高昂的成本使得小規模和新興 CRO 難以進入市場，可能阻礙市場成長。

技術進步

製藥和生物技術公司可以利用合約研究組織 (CRO) 的先進技術進行可靠且高效的臨床前試驗和數據分析，從而做出明智的藥物研發決策。 CRO 利用其專業知識降低研發風險，加速篩選有前景的候選藥物，並提高新治療方法的整體品質和安全性。此外，憑藉其專業知識和經驗，CRO 成為在高度監管的政府環境下推動藥物研發和創新的理想合作夥伴，從​​而擴大市場規模。

嚴格的法規環境

在該領域運作的合約研究組織（CRO）在應對複雜的法規結構面臨諸多挑戰，這可能導致合規成本增加和專案進度延誤。這種嚴格的法規環境也會影響製藥和生技公司在選擇CRO合作夥伴時的決策流程。此外，日益繁重的監管負擔導致核准流程延長和測試增多，從而影響CRO進行臨床前研究的整體效率和速度。這種不利的環境會抑制創新，減少臨床前研究服務的可近性，並最終阻礙市場擴張。

新冠疫情的感染疾病

新冠疫情對臨床前合約研究組織（CRO）市場造成了顯著的負面影響。臨床前試驗的延期和取消導致CRO服務需求下降。疫情帶來的經濟不確定性導致研發投入減少，進而影響了臨床前試驗外包的預算。此外，疫情造成的景氣衰退和不確定性迫使一些客戶推遲或取消臨床前項目，對CRO的收入和成長前景造成負面影響，並阻礙了市場的進一步擴張。

在預測期內，毒性測試領域預計將是規模最大的領域。

毒性測試領域預計將佔據最大的市場佔有率。專注於毒性測試的合約研究機構 (CRO) 透過對候選藥物進行全面評估，確保其符合嚴格的監管標準，從而為生物技術和製藥公司提供至關重要的服務。這些測試透過評估化學物質對各種生物系統的影響，幫助識別不良反應和劑量水平。因此，最大限度地降低研發風險、加快監管核准並確保藥物安全，有助於保護公眾健康和藥物研發的成功，最終推動該領域的成長。

在預測期內，患者來源異質骨移植（PDX）細分市場預計將呈現最高的複合年成長率。

由於PDX（患者來源異質骨移植）模型是將患者的腫瘤組織移植到免疫力缺乏小鼠體內，以模擬患者的腫瘤微環境，因此預計在預測期內，PDX細分市場將呈現最高的複合年成長率。這些模型能夠在更接近臨床實際的環境中評估候選藥物，進而提高藥物在人體臨床試驗中的成功率。此外，PDX合約研究組織（CRO）為個人化醫療提供了重要訊息，使針對特定患者的治療成為可能。精準醫療日益重要，使得PDX市場對於進一步推進高效標靶癌症治療至關重要，從而推動了該細分市場的擴張。

市佔率最大的地區：

在預測期內，亞太地區佔據了最大的市場佔有率，這主要得益於促進製藥公司和合約研究機構（CRO）之間順暢資料交換與協作的整合平台的發展。科文斯（Covance Inc.）、美德佩斯控股（Medpace Holdings, Inc.）、MPI Research 和歐陸科技（Eurofins Scientific）等領先企業為國際合作提供了極具吸引力的環境，並在全球製藥和生物技術產業發展中佔據了穩固的地位。此外，政府支持力度的加強、監管規範的統一以及高通量篩檢、機器學習和人工智慧等資料處理技術的進步，也推動了該地區的擴張。

複合年成長率最高的地區：

由於北美在支持製藥和生物技術公司進行藥物研發的臨床前階段方面發揮著至關重要的作用，預計該地區在預測期內將實現最高的複合年成長率。美國、加拿大和墨西哥地區擁有完善的基礎設施、最尖端科技和高技能人才。這些優勢涵蓋藥理學、毒理學、生物分析以及其他各種對獲得監管核准至關重要的臨床前試驗。此外，該地區的合約研究組織（CRO）受益於有利的法規環境以及與學術機構的合作，從而促進了創新和專業知識的積累，並推動了該地區的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球臨床前受託研究機構(CRO) 市場：依模式類型分類

  • 患者來源的異質骨移植（PDX）
  • 患者來源的類器官（PDO）

第6章 全球臨床前受託研究機構(CRO) 市場：依服務分類

  • 安全藥理學
  • 生物分析和藥物動力學（DMPK）研究
    • 體外藥物動力學（PK）
    • 藥物動力學（PK）
  • 毒性測試
  • 化學
    • 計算化學
    • 藥物化學
  • 化合物管理
    • 製程研究與開發
    • 客製合成
    • 其他化合物管理
  • 其他服務

第7章 全球臨床前受託研究機構（CRO）市場：依動物模型分類

  • 大型動物模型
  • 小型動物模型

第8章 全球臨床前受託研究機構（CRO）市場：依最終使用者分類

  • 政府和學術機構
  • 醫療設備製造商
  • 生物製藥公司
  • 其他最終用戶

第9章 全球臨床前受託研究機構（CRO）市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Crown Bioscience
  • Eurofins Scientific
  • Laboratory Corporation of America, Inc.
  • PRA Health Sciences, Inc.
  • Intertek Group Plc（IGP）
  • Wuxi AppTec
  • SGS SA（SGS）
  • Medpace, Inc.
  • Pharmaceutical Product Development（PPD）, LLC
  • Charles River Laboratories International, Inc.
  • PPD（Thermo Fisher Scientific, Inc.）
  • WuXi AppTec, Inc.（WAI）
Product Code: SMRC24604

According to Stratistics MRC, the Global Preclinical Contract Research Organization (CRO) Market is accounted for $6.4 billion in 2026 and is expected to reach $13.2 billion by 2034 growing at a CAGR of 9.5% during the forecast period. A Preclinical Contract Research Organization (CRO) is a specialized service provider in the pharmaceutical and biotechnology industry that conducts research and testing on experimental drugs and therapies before they enter clinical trials. To evaluate the safety, efficacy, and possible dangers associated with novel compounds, preclinical CROs provide a broad range of services. Furthermore, their knowledge and resources aid pharmaceutical businesses in optimizing drug development by offering vital information and regulatory support and by providing adherence to regulatory and industry norms.

According to the IFPMA's 2021 report, the annual R&D spending by the international biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Increase in globalization

CROs are international businesses that provide pharmaceutical and biotech firms with access to a wide range of resources, knowledge, and regulatory routes in several jurisdictions. By taking advantage of regulatory benefits, diversified patient populations, and developing markets, corporations can optimize their drug development strategy through globalization. Additionally, it improves healthcare outcomes and public access to cutting-edge therapeutics by encouraging cooperation and innovation and accelerating the time and efficiency of bringing new drugs to market.

Restraint:

High cost

The need to adhere to stringent regulatory regulations and uphold quality standards increases expenditures. To properly undertake preclinical research, CROs must invest a significant amount of money in cutting-edge facilities, machinery, and highly qualified staff. Intense competition is a common occurrence for CROs, which raises the price of marketing and business development initiatives. In addition, smaller or newly established CROs may find it difficult to enter the market due to these exorbitant costs, which thereby hinder market growth.

Opportunity:

Technological advancements

Pharmaceutical and biotech businesses may make well-informed judgments on drug development with the help of their advanced technologies, which enables them to provide reliable and efficient preclinical testing and data analysis. CROs use this specific knowledge to lower development risks, speed up the identification of promising drug candidates, and improve the general quality and safety of novel treatments. Furthermore, because of their specialization and experience, CROs are advantageous collaborators for promoting drug development and innovation in a tough, government-regulated setting thereby driving this market size.

Threat:

Stringent regulatory environment

CROs operating in this space encounter challenges in navigating the intricate regulatory frameworks, leading to increased compliance costs and potential delays in project timelines. The stringent regulatory environment also influences the decision-making process of pharmaceutical and biotechnology companies when selecting CRO partners. Furthermore, the regulatory load results in longer approval processes and more inspection, affects the general effectiveness and pace of preclinical research carried out by CROs. This unfavourable environment inhibits innovation, lowers the availability of preclinical research services, and thereby impedes this market expansion.

Covid-19 Impact

The COVID-19 pandemic has had a notable negative impact on the preclinical contract research organization (CRO) market. The number of preclinical studies that were postponed or cancelled resulted in a decline in the need for CRO services. The pandemic's financial insecurity has resulted in decreased investment in research and development, which has an effect on the money set aside for preclinical study outsourcing. Furthermore, the pandemic-induced economic downturn and uncertainty prompted some clients to postpone or cancel preclinical projects, impacting the revenue and growth prospects of CRO and further impeding this market.

The toxicology testing segment is expected to be the largest during the forecast period

The toxicology testing segment is estimated to hold the largest share. Toxicology-focused CROs offer vital services to biotech and pharmaceutical firms by thoroughly assessing potential drugs in order to satisfy strict regulatory standards. These tests help discover harmful reactions and dosage levels by assessing how chemicals affect different biological systems. Therefore, it protects public health and the success of drug development initiatives by minimizing development risks, expediting regulatory approvals, and guaranteeing the safety of pharmaceutical goods, which thereby boosts this segment's growth.

The patient derived xenograft (PDX) segment is expected to have the highest CAGR during the forecast period

The patient derived xenograft (PDX) segment is anticipated to have highest CAGR during the forecast period due to the tumor tissues from patients being transplanted into immunodeficient mice in PDX models to replicate the tumor environment of the patient. These models show a greater chance of success in human trials when drug candidates are evaluated in a more clinically appropriate setting. Furthermore, customized medicine insights are provided by PDX CROs, enabling treatmentsfor specific patients. The PDX market is essential for further developing efficient and targeted cancer treatments because of the growing significance of precision medicine, thereby driving this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the growth of integrated platforms that facilitate smooth data exchange and cooperation between pharmaceutical corporations and CROs. Key players such as Covance Inc., Medpace Holdings, Inc., MPI Research, and Eurofins Scientific offer a compelling environment for international collaborations and are establishing themselves in advancing the global pharmaceutical and biotechnology industries. Additionally, growing government support, regulatory harmonization, and technological advancements such as high-throughput screening, machine learning, and artificial intelligence for data processing drive this region's expansion.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to its pivotal role in supporting pharmaceutical and biotechnology companies in the preclinical phase of drug development. The United States, Canada, and Mexico regions are characterized by a robust infrastructure, cutting-edge technology, and a highly skilled workforce. They include pharmacology, toxicology, bioanalysis, and various other preclinical studies essential for regulatory approval. Furthermore, the region's CROs benefit from a favorable regulatory environment and collaboration with academic institutions, fostering innovation and expertise that are propelling this region's growth.

Key players in the market

Some of the key players in the Preclinical Contract Research Organization (CRO) Market include Crown Bioscience, Eurofins Scientific, Laboratory Corporation of America, Inc., PRA Health Sciences, Inc., Intertek Group Plc (IGP), Wuxi AppTec, SGS SA (SGS), Medpace, Inc., Pharmaceutical Product Development (PPD), LLC, Charles River Laboratories International, Inc., PPD (Thermo Fisher Scientific, Inc.) and WuXi AppTec, Inc. (WAI).

Key Developments:

In November 2023, Intertek, announced the launch of iCare in Turkiye, one of its most successful markets. iCare is an innovative one-stop digital portal providing textile manufacturers with a pioneering solution that enables seamless management and monitoring of their testing processes from start to finish.

In October 2023, SGS is signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors, headquartered in California.

In September 2023, Intertek, proudly announced the integration of advanced PhotonAssay technology into its Minerals laboratory facility in Tarkwa, Ghana. With a legacy of excellence and a commitment to innovation, Intertek Minerals aims to revolutionise gold industry support in West Africa through the implementation of this groundbreaking technology.

Model Types Covered:

  • Patient Derived Xenograft (PDX)
  • Patient Derived Organoid (PDOs)

Services Covered:

  • Safety Pharmacology
  • Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
  • Toxicology Testing
  • Chemistry
  • Compound Management
  • Other Services

Animal Models Covered:

  • Large Animal Model
  • Small Animal Model

End Users Covered:

  • Government and Academic Institutes
  • Medical Device Companies
  • Biopharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preclinical Contract Research Organization (CRO) Market, By Model Type

  • 5.1 Introduction
  • 5.2 Patient Derived Xenograft (PDX)
  • 5.3 Patient Derived Organoid (PDOs)

6 Global Preclinical Contract Research Organization (CRO) Market, By Service

  • 6.1 Introduction
  • 6.2 Safety Pharmacology
  • 6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
    • 6.3.1 In vitro Pharmacokinetics (PK)
    • 6.3.2 In-vivo Pharmacokinetics (PK)
  • 6.4 Toxicology Testing
  • 6.5 Chemistry
    • 6.5.1 Computation Chemistry
    • 6.5.2 Medicinal Chemistry
  • 6.6 Compound Management
    • 6.6.1 Process R&D
    • 6.6.2 Custom Synthesis
    • 6.6.3 Other Compound Managements
  • 6.7 Other Services

7 Global Preclinical Contract Research Organization (CRO) Market, By Animal Model

  • 7.1 Introduction
  • 7.2 Large Animal Model
  • 7.3 Small Animal Model

8 Global Preclinical Contract Research Organization (CRO) Market, By End User

  • 8.1 Introduction
  • 8.2 Government and Academic Institutes
  • 8.3 Medical Device Companies
  • 8.4 Biopharmaceutical Companies
  • 8.5 Other End Users

9 Global Preclinical Contract Research Organization (CRO) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Crown Bioscience
  • 11.2 Eurofins Scientific
  • 11.3 Laboratory Corporation of America, Inc.
  • 11.4 PRA Health Sciences, Inc.
  • 11.5 Intertek Group Plc (IGP)
  • 11.6 Wuxi AppTec
  • 11.7 SGS SA (SGS)
  • 11.8 Medpace, Inc.
  • 11.9 Pharmaceutical Product Development (PPD), LLC
  • 11.10 Charles River Laboratories International, Inc.
  • 11.11 PPD (Thermo Fisher Scientific, Inc.)
  • 11.12 WuXi AppTec, Inc. (WAI)

List of Tables

  • Table 1 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 3 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 4 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 5 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 6 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 7 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 8 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 9 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 10 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 11 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 12 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 13 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 14 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 15 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 16 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 17 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 18 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 19 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 20 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 21 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 22 Global Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 24 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 25 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 26 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 27 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2023-2034) ($MN)
  • Table 28 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 29 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 30 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 31 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 32 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 33 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 34 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 35 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 36 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 37 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 38 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 39 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 40 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 41 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 42 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 43 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 44 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 45 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 46 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 47 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 48 North America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 50 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 51 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 52 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 53 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2023-2034) ($MN)
  • Table 54 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 55 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 56 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 57 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 58 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 59 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 60 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 61 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 62 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 63 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 64 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 65 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 66 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 67 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 68 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 69 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 70 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 71 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 72 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 73 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 74 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 75 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 76 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 77 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 78 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 79 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2023-2034) ($MN)
  • Table 80 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 81 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 82 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 83 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 84 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 85 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 86 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 87 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 88 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 89 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 90 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 91 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 92 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 93 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 94 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 95 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 96 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 97 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 98 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 99 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 100 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 101 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 102 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 103 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 104 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 105 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2023-2034) ($MN)
  • Table 106 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 107 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 108 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 109 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 110 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 111 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 112 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 113 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 114 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 115 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 116 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 117 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 118 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 119 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 120 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 121 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 122 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 123 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 124 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 125 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 126 South America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 127 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 128 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 129 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 130 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 131 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2023-2034) ($MN)
  • Table 132 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2023-2034) ($MN)
  • Table 133 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2023-2034) ($MN)
  • Table 134 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2023-2034) ($MN)
  • Table 135 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2023-2034) ($MN)
  • Table 136 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2023-2034) ($MN)
  • Table 137 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2023-2034) ($MN)
  • Table 138 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 139 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2023-2034) ($MN)
  • Table 140 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2023-2034) ($MN)
  • Table 141 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2023-2034) ($MN)
  • Table 142 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2023-2034) ($MN)
  • Table 143 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2023-2034) ($MN)
  • Table 144 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2023-2034) ($MN)
  • Table 145 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2023-2034) ($MN)
  • Table 146 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2023-2034) ($MN)
  • Table 147 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2023-2034) ($MN)
  • Table 148 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2023-2034) ($MN)
  • Table 149 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2023-2034) ($MN)
  • Table 150 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2023-2034) ($MN)
  • Table 151 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2023-2034) ($MN)
  • Table 152 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2023-2034) ($MN)
  • Table 153 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2023-2034) ($MN)
  • Table 154 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 155 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2023-2034) ($MN)
  • Table 156 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2023-2034) ($MN)